Dual S100A1 and ARC gene therapy as a treatment for DMD cardiomyopathy

Area of Science:

• Cardiovascular Research
• Gene Therapy
• Neuromuscular Disorders

Background:

• Duchenne muscular dystrophy (DMD) is a fatal pediatric muscle disease with no cure.
• Cardiomyopathy is the primary cause of death in DMD patients, representing a significant unmet clinical need.
• Current therapeutic options for DMD cardiomyopathy are limited.

Purpose of the Study:

• To investigate adeno-associated viral (AAV) gene therapy for DMD cardiomyopathy.
• To evaluate the efficacy of overexpressing S100A1 and apoptosis repressor with caspase recruitment domains (ARC) in DMD models.
• To assess the safety and functional benefits of combined S100A1-ARC gene therapy.

Main Methods:

• Utilized the severe D2.mdx mouse model of DMD.
• Employed adeno-associated viral (AAV) vectors for gene delivery.
• Administered gene therapy via intracoronary delivery in a canine model of DMD.

Main Results:

• S100A1 gene therapy improved diastolic dysfunction in DMD cardiomyopathy.
• ARC gene therapy demonstrated a survival benefit in DMD models.
• Combined S100A1-ARC gene therapy improved long-term cardiac outcomes and showed safety in canine models.
• S100A1-ARC gene therapy also benefited skeletal muscle function in D2.mdx mice.

Conclusions:

• S100A1-ARC gene therapy is an effective treatment for DMD cardiomyopathy.
• This therapeutic approach may also be beneficial for other forms of cardiomyopathy and muscle pathologies.
• The findings support S100A1-ARC gene therapy as a promising treatment strategy for DMD.